Global CAR-T Experts
Sign up for a session and connect with a CAR-T expert.
Each session will be limited to 10 participants. Please register at your earliest convenience to reserve a seat.
-
New Sessions in FL and pALL Coming Soon
Click the Get Notified Button to be the First to Know!
Previous Sessions
-
Ulf Schnetzke, MD
Senior Physician, Jena University Hospital
Germany
Radiation Prior to CAR-T Infusion – a Promising Bridging Strategy to Optimize Outcomes
Dr. Ulf Schnetzke is a senior physician in the Department of Hematology and Internal Oncology. He has an interest in lymphomas and optimizing patient outcomes with CAR-T cell therapy.
-
Antonia Müller, MD
Professor Cellular Therapy and Transfusion Medicine, MedUni Vienna
Austria
Role of Bone-marrow Assessment Before and After CAR-T Infusion
Dr. Müller has participated in a number of pivotal CAR-T trials (including BELINDA). She has a particular interest in sharing her expertise in optimizing the treatments of lymphoma and promoting the importance of interdisciplinary teams in effective disease management.
-
Antonia Müller, MD
Professor Cellular Therapy and Transfusion Medicine, MedUni Vienna
Austria
Role of Prophylactic and Preemptive Steroids in CAR-T Cell Treatment
Dr. Müller has participated in a number of pivotal CAR-T trials (including BELINDA). She has a particular interest in sharing her expertise in optimizing the treatments of lymphoma and promoting the importance of interdisciplinary teams in effective disease management.
-
Antonia Müller, MD
Professor Cellular Therapy and Transfusion Medicine, MedUni Vienna
Austria
Potential Way to Improve Existing/Approved CAR-T Cell Therapy by In Vivo Immunomodulation
Dr. Müller has participated in a number of pivotal CAR-T trials (including BELINDA). She has a particular interest in sharing her expertise in optimizing the treatments of lymphoma and promoting the importance of interdisciplinary teams in effective disease management.
-
Satoshi Yoshihara, MD
Associate Professor, Hyogo College of Medicine
Japan
Bridging Therapy, Focusing on the Use of Pola-BR (Efficacy and AE)
Dr. Yoshihara has broad experience in real-world treatment of patients with CAR-T therapy for lymphoma, ALL, and myeloma. He is particularly interested in investigating approaches aimed to improve real-world CAR-T Therapy outcomes by enhancing T-cell collection efficiency, optimizing bridging therapy, and management of adverse events.
Additional sessions in FL and pALL coming later this summer.
Sign up below to be the first to know!
This is a paid promotion by Novartis. By registering for this event, you agree that your personal data will be processed in accordance with the Novartis Privacy Policy.